What ends up in the bottle.

In October 2025, a Channel 4 News investigation showed the world what happens when an unregulated reseller dresses up cheap research material as a miracle drug. Here is what the Synedica case tells every peptide buyer about what is actually in the pen.

An unregulated injection pen sold as an investigational peptide. Swap with a real editorial photo by dropping one into /images/blog/bottle-hero.jpg.

The Synedica case, in short

On 22 October 2025, a Channel 4 News investigation in the United Kingdom exposed a company called Synedica selling injection pens marketed as retatrutide, a triple-agonist GLP-1 peptide that is still in Phase 3 clinical trials and has not been approved for human use in any country in the world.

The pens were sold online and on social media. The packaging and positioning implied the product came from the manufacturer running the trials, Eli Lilly. A second company, Alluvi, was named alongside Synedica in the same supply chain. When the Channel 4 reporter sent Eli Lilly a sample of the product, the company confirmed the pens were not theirs. They were counterfeit.

Following the broadcast, Eli Lilly publicly announced it would take legal action against both companies. Synedica's own website carries a disclaimer saying the product is "for research use only," which is the same four words almost every grey-market peptide reseller uses. In practice the pens were being marketed to the general public as a weight-loss drug, and distributing an investigational peptide outside of a clinical trial is illegal on both sides of the Atlantic.

The Synedica story is not unusual. It is this year's version of a pattern that has repeated inside the peptide industry for at least a decade. A company puts a logo on a website, orders drums of crude research material from an unregulated manufacturer in Hebei, Shandong or Sichuan, and relabels it. The markup is six to ten times. The quality control is a generic PDF. The product is sold under a "research use only" disclaimer that nobody believes.

The problem is not that the peptide was synthesised in China. Credible peptide chemistry happens in China every day, inside GMP-certified facilities audited by the FDA, EMA or MHRA. The problem is who synthesised a particular lot, under what conditions, and whether anyone ever tested it after it crossed the border.

What independent testing keeps finding

When academic labs, regulators, or sceptical buyers send anonymously-purchased peptides to a credible analytical laboratory, the results cluster into a short list of problems. These are the ones that show up over and over.

1. Wrong identity

The label says BPC-157. The mass spectrometer says something close, but not that. A single amino acid substituted, a residue missing, a different acetylation pattern. The buyer thinks they bought a well-studied peptide. They bought an unknown one with no literature.

2. Low actual purity

The CoA claims greater than ninety-eight percent by HPLC. Independent testing finds a main peak at eighty-four percent, surrounded by synthesis byproducts and deletion sequences no one bothered to remove. The target peptide is diluted with impurities the buyer never paid for.

3. Bacterial endotoxins

This is the one that can actually hurt someone. Endotoxins are fragments of bacterial cell walls. Unregulated synthesis facilities do not control for them, because they do not have to. Endotoxin-contaminated peptide reconstituted in bacteriostatic water and injected produces a classic pyrogenic response: fever, chills, hypotension. In research use, it confounds the data. Outside research, the consequences are worse.

4. Residual solvents

Peptide synthesis uses dichloromethane, DMF, acetonitrile, and trifluoroacetic acid. Every legitimate facility runs gas chromatography to confirm those solvents have been removed. Many Chinese research-chemical facilities do not. Buyers end up with measurable DCM or TFA in their pens. The peptide still "works." The pen is still toxic.

5. Heavy metals

Peptide synthesis resins and scavengers contain trace palladium, copper, and iron. Legitimate release testing includes ICP-MS to confirm the metals have been removed within pharmacopoeial limits. Cheap manufacturers skip this test because the test itself costs more than the peptide.

Why the reseller model rewards this

A US or EU peptide website has one job. Buy low, mark up, ship. The economics make anything else unaffordable.

A credible lot release package in Europe costs between eight hundred and two thousand euros per batch, depending on the panel. Third-party endotoxin testing alone is three to five hundred euros. A proper ICP-MS heavy metals panel is another few hundred. Residual solvents by GC. Microbial limits. Water content by Karl Fischer.

If you are reselling ten-euro-a-gram research chemicals at eighty euros a gram, you cannot afford to run that testing. So you do not. You copy the supplier's CoA, put your own logo on it, and ship.

The buyer never finds out, because the buyer never tests. Research-use-only labelling means nobody has to. Until someone does, and the headline comes.

The three questions that catch a reseller

If you are buying peptides from anyone, ask these three questions before you pay. If the answer to any of them is evasive, the supplier is a reseller, and what is in the bottle is a guess.

What we do differently

Aevivo does not manufacture peptides. We do not pretend to. What we do is source from a single, named European GMP-certified facility, test every lot, and publish the release package tied to the batch you receive.

The facility is disclosed to buyers who ask. The release panel includes HPLC, MS, residual solvents, water content, and appearance as standard. Endotoxin testing is performed on every lot of parenteral-format peptides. Heavy metals are tested on every lot where synthesis chemistry introduces them.

None of that is heroic. It is what the reseller model cannot afford to do, and it is why the reseller model ships what it ships. We chose a different model so we could ship something different.